Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Recruiting · NCT05414032 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Recruiting | Phase 2 | 2026-10-05 | NCT05414032 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| NeoGenomics Laboratories, Inc. | 1 |
| Personalis Inc. | 6 |
| University Health Network, Toronto | 417 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Princess Margaret Cancer Centre | Toronto | Canada | 12 |